Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
2
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 7 publications
1
2
0
Order By: Relevance
“…Cell lines in cluster C4 are predicted to be sensitive to multiple families of drugs, including RAF, KIT, PDGFR, and PI3K/mTOR inhibitors. This agrees with current clinical practice which uses mTOR and BRAF inhibitors as first-line therapy for kidney cancer and melanoma, respectively (58, 59), since the c-Met/mTOR axis is frequently altered in kidney cancer (60, 61) while BRAF mutations are the main genetic drivers of melanoma (59). Finally, RTKs are frequently altered in glioblastoma (62, 63).…”
Section: Resultssupporting
confidence: 88%
“…Cell lines in cluster C4 are predicted to be sensitive to multiple families of drugs, including RAF, KIT, PDGFR, and PI3K/mTOR inhibitors. This agrees with current clinical practice which uses mTOR and BRAF inhibitors as first-line therapy for kidney cancer and melanoma, respectively (58, 59), since the c-Met/mTOR axis is frequently altered in kidney cancer (60, 61) while BRAF mutations are the main genetic drivers of melanoma (59). Finally, RTKs are frequently altered in glioblastoma (62, 63).…”
Section: Resultssupporting
confidence: 88%
“…In ccRCC, mTOR is one of the most frequently mutated genes [4], and the mTOR pathway is regularly activated [18,19]. mTOR exerts its effects as part of two protein complexes, mTOR complex 1 and 2 (mTORC1/2).…”
Section: Resultsmentioning
confidence: 99%
“…mTOR signaling links multiple receptors and oncogenes to cell growth, protein translation, metabolism, cell invasion and cell-cycle via downstream effectors such as p70 ribosomal protein S6 kinase (p70S6K) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) (86,87). mTOR inhibitors temsirolimus and afinitor, both rapamycin analogues, have been approved for treatment of ccRCC (88)(89)(90).…”
Section: Mir-99a (Mtor) Mir-99a (Figurementioning
confidence: 99%